These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 9629530)
21. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Levin JI Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727 [TBL] [Abstract][Full Text] [Related]
22. A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis. Simard N; Boire G; de Brum-Fernandes AJ; St-Pierre Y Arthritis Res Ther; 2006; 8(4):R125. PubMed ID: 16859524 [TBL] [Abstract][Full Text] [Related]
23. Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors. Kannan R; Ruff M; Kochins JG; Manly SP; Stoll I; El Fahime M; Noël A; Foidart JM; Rio MC; Dive V; Basset P Protein Expr Purif; 1999 Jun; 16(1):76-83. PubMed ID: 10336863 [TBL] [Abstract][Full Text] [Related]
24. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors. Campbell DA; Xiao XY; Harris D; Ida S; Mortezaei R; Ngu K; Shi L; Tien D; Wang Y; Navre M; Patel DV; Sharr MA; DiJoseph JF; Killar LM; Leone CL; Levin JI; Skotnicki JS Bioorg Med Chem Lett; 1998 May; 8(10):1157-62. PubMed ID: 9871727 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Naito K; Nakajima S; Kanbayashi N; Okuyama A; Goto M Agents Actions; 1993 Jul; 39(3-4):182-6. PubMed ID: 8304246 [TBL] [Abstract][Full Text] [Related]
27. Implication of interleukin 18 in production of matrix metalloproteinases in articular chondrocytes in arthritis: direct effect on chondrocytes may not be pivotal. Dai SM; Shan ZZ; Nishioka K; Yudoh K Ann Rheum Dis; 2005 May; 64(5):735-42. PubMed ID: 15834055 [TBL] [Abstract][Full Text] [Related]
28. Isolation of nicotianamine as a gelatinase inhibitor. Suzuki K; Shimada K; Nozoe S; Tanzawa K; Ogita T J Antibiot (Tokyo); 1996 Dec; 49(12):1284-5. PubMed ID: 9031677 [No Abstract] [Full Text] [Related]
29. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829 [TBL] [Abstract][Full Text] [Related]
30. Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis. Seftor EA; Seftor RE; Nieva DR; Hendrix MJ Adv Dent Res; 1998 Nov; 12(2):103-10. PubMed ID: 9972131 [No Abstract] [Full Text] [Related]
32. Metalloproteinase inhibitors as therapeutics. Gordon JL; Drummond AH; Galloway WA Clin Exp Rheumatol; 1993; 11 Suppl 8():S91-4. PubMed ID: 8391953 [TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835 [TBL] [Abstract][Full Text] [Related]
34. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Borkakoti N; Winkler FK; Williams DH; D'Arcy A; Broadhurst MJ; Brown PA; Johnson WH; Murray EJ Nat Struct Biol; 1994 Feb; 1(2):106-10. PubMed ID: 7656013 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041 [TBL] [Abstract][Full Text] [Related]